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Mesenchymal stromal cells (MSC) have important immunomodulatory properties, they
inhibit T lymphocyte allo-activation and have been used to treat graft-versus-host disease.
How MSC exert their immunosuppressive functions is not completely understood but
species speciﬁc mechanisms have been implicated. In this study we have investigated the
mechanisms for rat MSC mediated inhibition ofT lymphocyte proliferation and secretion of
inﬂammatory cytokines in response to allogeneic and mitogenic stimuli in vitro. MSC inhib-
ited the proliferation of T cells in allogeneic mixed lymphocyte reactions and in response
to mitogen with similar efﬁcacy. The anti-proliferative effect was mediated by the induced
expression of nitric oxide (NO) synthase and production of NO by MSC.This pathway was
required and sufﬁcient to fully suppress lymphocyte proliferation and depended on prox-
imity of MSC and target cells. Expression of inducible NO synthase by MSC was induced
through synergistic stimulation with tumor necrosis factor α and interferon γ secreted
by activated lymphocytes. Conversely, MSC had a pronounced inhibitory effect on the
secretion of these cytokines by T cells which did not depend on NO synthase activity or
cell contact, but was partially reversed by addition of the cyclooxygenase (COX) inhibitor
indomethacin. In conclusion, rat MSC use different mechanisms to inhibit proliferative and
inﬂammatory responses of activated T cells. While proliferation is suppressed by produc-
tion of NO, cytokine secretion appears to be impaired at least in part by COX-dependent
production of prostaglandin E2.
Keywords: mesenchymal stem cells, immunosuppression, T lymphocyte activation, mixed lymphocyte reaction,
nitric oxide synthase 2, cytokines, rodent, prostaglandin E2
INTRODUCTION
Mesenchymal stem cells have self-renewing capacity and differ-
entiation potential for all mesodermal cell lineages (Pittenger
et al., 1999). They are present within a heterogeneous cell pop-
ulation referred to as mesenchymal stromal cells (MSC) which are
presently deﬁned by a set of criteria based on their morphology,
phenotype, and multipotency (Dominici et al., 2006). To date,
MSC have been studied most thoroughly in humans and mice.
They can be isolated from the bone marrow (BM) and a variety
of other adult and fetal tissues (Pittenger et al., 1999; Zuk et al.,
2001; in ’t Anker et al., 2003, 2004; da Silva Meirelles et al., 2006;
Yoshimura et al., 2007). MSC have potent modulatory effects on
immune cells including T cells, B cells, natural killer cells, and
dendritic cells as well as regulatory T (Treg) cells (Uccelli et al.,
2006; Nauta and Fibbe, 2007; Tolar et al., 2011). A range of dis-
tinctmediatormolecules have been implicated (Uccelli et al., 2006;
Nasef et al., 2008) but the molecular mechanisms by which MSC
exert these effects are not entirely understood and the inﬂuences
of tissue source, species origin, and cell culture conditions have yet
to be ﬁrmly established.
Nitric oxide (NO) is a short-lived bioactive compound which
is catalyzed by different tissue-speciﬁc NO synthases, of which
inducibleNO synthase (iNOS) encoded by the NOS2 gene is active
in macrophages, ﬁbroblasts, and endothelial cells (Bogdan, 2001;
Lukacs-Kornek et al., 2011). iNOS expression can be induced by
synergistic signals of interferon (IFN) γ and tumor necrosis fac-
tor (TNF) α or Toll-like receptor (TLR) ligands (Liew et al., 1991;
Muñoz-Fernández et al., 1992; Deng et al., 1993; Lorsbach et al.,
1993; Lukacs-Kornek et al., 2011). NO acts as a regulator of cel-
lular and immune functions (Bogdan, 2001) such as inhibition
of T cell responses (Lejeune et al., 1994; Medot-Pirenne et al.,
1999; Niedbala et al., 2006) and induction of Treg cells (Niedbala
et al., 2007). The iNOS pathway also has a role in the immuno-
suppressive potential of MSC (Sato et al., 2007). A combination of
pro-inﬂammatory cytokines, namely IFNγ together with TNFα,
interleukin (IL)1α, or IL1β, has been shown to trigger the expres-
sionof iNOS inmurineBM-derivedMSC (Ren et al., 2008).Mouse
MSC (mMSC) utilize NO to arrest T cell proliferation and acti-
vation in vitro and in vivo (Oh et al., 2007; Sato et al., 2007; Ren
et al., 2008).
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The capacity of MSC to suppress the activation of T lympho-
cytes has become of interest for clinical prevention and treat-
ment of both autoimmune diseases and graft-versus-host disease
(GVHD;Dazzi and Krampera, 2011; Tolar et al., 2011). GVHD has
been treated successfully with MSC infusions clinically (Le Blanc
et al., 2004, 2008; Ringdén et al., 2006; Martin et al., 2010; Tolar
et al., 2011) and experimentally in animal models (Yanez et al.,
2006; Min et al., 2007; Tisato et al., 2007; Polchert et al., 2008;
Tian et al., 2008; Joo et al., 2010). Ren et al. (2008) reported that
amelioration of experimental GVHD by mMSC depended on NO
production. Human MSC (hMSC), on the other hand, do not uti-
lize NO conversion, but rather employ alternative signaling path-
ways such as indoleamine-2,3-dioxygenase (IDO), cyclooxygenase
(COX)-2 required for synthesis of prostaglandin E2 (PGE2), and
heme oxygenase-1 expression to inhibit T cell activation and
induce expansion of Treg cells (Meisel et al., 2004; Aggarwal and
Pittenger, 2005; Ren et al., 2009; Mougiakakos et al., 2011).
It has been suggested that MSC are “licensed” by certain effec-
tor molecules to exert immunomodulatory functions (Dazzi and
Krampera, 2011). When exposed to an inﬂammatory milieu,
hMSC upregulated the expression of IDO and COX-2 genes and
showed increased inhibitory potential in mixed lymphocyte reac-
tions (MLR; Crop et al., 2010). In another recent paper, the
immunomodulatory properties of rat MSC (rMSC) were primed
by the addition of different cytokines resulting in either enhanced
inhibition of proliferation or the opposite effect depending on the
type of stimulatory signal (Renner et al., 2009).
In this report, we generated rMSC lines from the BM and eval-
uated their potential to inhibit T cell proliferation and cytokine
secretion in vitro.We show that the regulation of immunosuppres-
sion by rMSC was more similar to mouse than to hMSC. rMSC
depended on cell-to-cell contact, iNOS expression, and NO pro-
duction to mediate potent anti-proliferative effects. The putative
mechanism that inhibits secretion of inﬂammatory cytokines is
distinct and does not depend on cellular contact but on a soluble
factor, likely PGE2 produced by COX-2.
MATERIALS AND METHODS
ETHICS STATEMENT
Approval for the use of organs of rats euthanizedwithCO2 (license
number: VIT09.1512) was obtained from our institutional vet-
erinarian with delegated authority from the Norwegian Animal
Research Authority under the Ministry of Agriculture of Norway.
All experiments were conducted in compliance with institutional
guidelines. All animals were sacriﬁced with CO2 and every effort
was made to minimize their suffering.
ANIMAL CARE
PVG strain rats express the c haplotype of the rat MHC (RT1c,
i.e., RT1-Ac-B/Dc-CE/N/Mc; for short, c-c-c). PVG-RT7b strain
(abbreviated PVG.7B) rats express the RT7.2 allotype of CD45,
but are used interchangeablywith the standard PVG strain (encod-
ing the RT7.1 allotype) as both strains carry the RT1c haplotype.
The MHC-congenic PVG-RT1u strain (PVG.1U) expresses the u-
u-u MHC haplotype, the PVG-RT1n strain (PVG.1N) the n-n-n
haplotype and the intra-MHC recombinant PVG-RT1r23 strain
(PVG.R23) the u-a-av1 haplotype on the PVG background.
PVG.R23, PVG.1N, PVG.1U, and PVG.7B rats were bred at
the Institute of Basic Medical Sciences, University of Oslo. PVG
and BN/RijHsd (BN; RT1n, n-n-n) rats were purchased from
Harlan, The Netherlands1. The animals were housed under a
12:12 h light/dark cycle with access to food and ﬁltered drink-
ing water ad libitum and were routinely screened for common
pathogens following recommendations by the Federation of Euro-
pean Laboratory Animal Science Associations (Nicklas et al.,
2002).
MATERIALS
Nylon cell strainers (70μm mesh size) were purchased from
BD Falcon, MA, USA2; GIBCO® RPMI medium 1640, OPTI-
MEM® I, α-modiﬁed minimal essential medium, fetal bovine
serum (FBS), penicillin and streptomycin, sodium pyruvate, 2-
mercaptoethanol, trypsin and EDTA, lipopolysaccharide (LPS),
polyinosinic:polycytidylic acid (poly-I:C) from Invitrogen, UK3;
l-glutamine, Immobilon®-P transfer membrane from Milli-
pore, MA, USA4; biotin, Brefeldin A, Concanavalin A (ConA),
sodium nitrate, sodium dodecyl sulfate, 2-mercaptoethanol,
glycerol, sulfanilamide, N -(1-Naphthyl) ethylenediamine dihy-
drochloride, 5(6)-carboxyﬂuorescein diacetate n-succinimidyl
ester (CFSE), ﬂuorescein isothiocyanate (FITC), propidium
iodide, paraformaldehyde, saponin from Quillaja bark, 1-methyl-
dl-tryptophan (1-MT), NG-monomethyl-l-arginine acetate (l-
NMMA) from Sigma-Aldrich, MO, USA5; indomethacin (IMC;
Confortid®) from Dumex-Alpharma A/S, Denmark6; Criterion™
Precast gels from Bio-Rad Laboratories, CA, USA7; SuperSignal®
West Pico chemiluminescent substrate from Thermo Scientiﬁc,
IL, USA8; Amersham Hyperﬁlm™ ECL from GE Healthcare Ltd.,
UK9; culture ﬂasks from Nunc, Denmark10; 96-well cell cul-
ture clusters, HTS Transwell® 96-well system with 0.4μm poly-
carbonate membrane insert plates from Corning, NY, USA11;
recombinant rat IFNγ from Biomedical Primate Research Cen-
tre, The Netherlands12; recombinant rat TNFα from Pepro-
Tech, UK13; [methyl-3H]-thymidine (3H-TTP) from Hartmann-
Analytic, Germany14; MicroScint™ O solution from PerkinElmer,
MA, USA15.
ANTIBODIES
Monoclonal mouse anti-rat CD25 (OX39) and anti-CD3
(G4.18) antibodies were conjugated with biotin and anti-CD4
(W3/25) antibody with FITC in our laboratory using stan-
dard methods. Supernatants of monoclonal mouse anti-rat
1www.harlan.com
2www.bdbiosciences.com
3www.invitrogen.com
4www.millipore.com
5www.sigma-aldrich.com
6www.alpharma.com
7www.bio-rad.com
8www.piercenet.com
9www.gelifesciences.com
10www.nuncbrand.com
11www.corning.com
12www.bprc.nl
13www.peprotech.com
14www.hartmann-analytic.de
15www.perkinelmer.com
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CD45 (OX1), anti-RT1-B/D (pan-MHC class II; OX6), anti-CD71
(OX26), anti-CD11b (OX42), anti-CD86 (OX48), anti-CD44
(OX49), anti-RT1-A (pan-MHC class I; OX18, puriﬁed) anti-
bodies, as well as phycoerythrin-conjugated mouse anti-rat IFNγ
(DB-1), anti-CD31 (TLD-3A12), anti-CD90 (OX7), anti-CD3
(G4.18), FITC-conjugated anti-CD59 (TH9) from BD Biosciences
and allophycocyanin-conjugated rat anti-mouse/rat FoxP3 (FJK-
16s) from eBioscience, CA,USA16 were used for immunostaining.
Phycoerythrin-conjugated donkey anti-mouse immunoglobulin
(Ig) G or peridinin chlorophyll protein-conjugated Streptavidin
from BD Biosciences were used as secondary antibodies for ﬂow
cytometric analysis.
Polyclonal rabbit anti-rat TNFα, goat anti-rat IFNγ, and rabbit
anti-rat IL6 antibodies were from PeproTech; polyclonal rab-
bit anti-rat NOS2 (M-19) from Santa Cruz Biotechnology, CA,
USA17; monoclonal mouse anti-GAPDH (6C5) from Millipore;
horseradish peroxidase-conjugated goat anti-rabbit IgG and goat
anti-mouse IgG from Jackson ImmunoResearch, PA, USA18.
CELL LINES
The rat macrophage cell line R2 is derived from pleural
macrophages induced by a silica injection in the pleural cavity
of Wistar rats (Damoiseaux et al., 1994). R2 cells were maintained
in complete medium comprising RPMI 1640 supplemented with
10% heat-inactivated FBS, 100UmL−1 penicillin, 100μgmL−1
streptomycin, 2mM l-glutamine, 1mM sodium pyruvate and
50μM 2-mercaptoethanol at 37˚C in a humidiﬁed atmosphere
of 5% CO2.
MSC lines were obtained from 7- to 8-week-old female PVG.7B
and PVG.1U rats as described elsewhere (Lennon and Caplan,
2006). In short, BM cells were aspirated from femurs and tibias, ﬁl-
tered throughnylon cell strainers, and cultured inα-modiﬁedmin-
imal essential medium supplemented with 20% FBS, 100UmL−1
penicillin, 100μgmL−1 streptomycin, and 2mM l-glutamine in
175 cm2 culture ﬂasks at 37˚C in a humidiﬁed atmosphere of 5%
CO2. Non-adherent cells were removed after 24 h by replacement
of culture medium with complete, antibiotics-free MSC medium
comprising α-modiﬁed minimal essential medium supplemented
with 15% FBS and 2mM l-glutamine. Adherent cells were allowed
to expand to near conﬂuence,detached using 500μgmL−1 trypsin
and 200μgmL−1 EDTA·4Na and reseeded at a density of approx-
imately 400–600 cells cm−2. MSC were used in experiments after
the third passage. Supernatants from conﬂuent cultures were fre-
quently controlled for mycoplasma contamination by PCR as
previously described (Zinöcker et al., 2011b).
CELL CULTURE
Mesenteric and cervical lymph nodes from 7- to 14-week-old
male or female PVG, PVG.7B, PVG.1N, PVG.1U, PVG.R23, and
BN rats were removed and ﬁltered through nylon cell strainers.
The lymphocyte population was puriﬁed by density gradient cen-
trifugation using Lymphoprep™ 1.077 (Medinor AS, Norway)19.
16www.ebioscience.com
17www.scbt.com
18www.jacksonimmuno.com
19www.medinor.no
Stimulator cells were irradiated (2000 cGy) using a 137Cs source
(Gammacell® 3000; MDS Nordion, ON, Canada)20 to inhibit
mitosis. MLR were performed in a total volume of 200 μL com-
plete MLR medium comprising RPMI 1640 supplemented with
10% heat-inactivated FBS, 100UmL−1 penicillin, 100μgmL−1
streptomycin, 2mM l-glutamine, and 50μM 2-mercaptoethanol
using round bottom 96-well plates. Equal numbers (2× 105) of
responder and stimulator cells were mixed and incubated for
4 days at 37˚C in a humidiﬁed atmosphere of 5% CO2. ConA
was used at 5μgmL−1 ﬁnal concentration for mitogenic stimu-
lation of 2× 105 responder cells unless speciﬁed otherwise. MSC
were harvested from culture, washed twice (500 g for 6min) in
phosphate-buffered saline (PBS), resuspended in MLR medium
and seeded at least 2 h before lymphocytes were added to allow
attachment.
For stimulation experiments, cell-free supernatants were cen-
trifuged at 400× g for 10min before transfer of equal volumes to
MSC culture. For transwell experiments, MSC were seeded either
in 0.4μm polycarbonate membrane inserts or in the reservoirs of
96-well ﬂat-bottom receiver plates. Responder cells were added to
the bottom reservoirs and co-incubated for 3 days.
RADIONUCLIDE INCORPORATION ASSAY
DNA synthesis during mitogen stimulation or mixed lymphocyte
culture was assessed after 20 h pulsing with 1 μCi 3H-TTP before
termination of the culture. Cells were harvested on glass ﬁber
ﬁlters using a Filtermate 196 cell harvester (Packard Bioscience
Co., CT, USA)21 and radioactivity was measured using a Wallac
1450 MicroBeta® TriLux (PerkinElmer) microplate scintillation
counter. Relative inhibition of the culture was calculated by the
following equation:
inhibition = 1 − (proliferation count of the sample/
mean proliferation count of the positive control)
CFSE DILUTION ASSAY
Responder cells were stained with CFSE prior to in vitro culture
as previously described (Zinöcker et al., 2011b). Brieﬂy, cells were
resuspended in OPTI-MEM at 2× 106 mL−1 and incubated with
0.5μM CFSE for 10min at 37˚C. Stained cells were then washed
(400 g for 8min) in MLR medium, incubated once more for 5min
at 37˚C, washed twice and resuspended in MLR medium.
At the termination of MLR and ConA cultures, cells were
harvested and washed in PBS before immunostaining and ﬂow
cytometric analysis. Fiftymicromolar propidium iodidewas added
before ﬂow cytometric analysis to exclude non-viable cells. The
percentage of dividing cells was determined as the fraction of cells
that had undergone one or several cell divisions (CFSElo) relative
to the total number of CFSE+ cells including cells that had not
undergone cell divisions (CFSEhi).
IMMUNOSTAINING AND FLOW CYTOMETRIC ANALYSIS
All MSC lines were tested for surface marker expression by ﬂow
cytometry. Cells were labeled with anti-CD11b, -CD31, -CD44, -
CD45, -CD59, -CD71, -CD86, -CD90, anti-class I, and anti-class II
20www.mds.nordion.com
21www.packardbioscience.com
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MHC monoclonal antibodies (cf. Antibodies). Monoclonal mouse
IgG1 and IgG2a were used as isotype controls.
For intracellular IFNγ staining, Brefeldin A (10μgmL−1) was
added 4 h prior to termination of ConA-stimulated LNC cultures
to inhibit protein secretion. Cells from triplicate or quadruplicate
wells were pooled, stained with anti-CD3 antibody, ﬁxed with 4%
paraformaldehyde in PBS, permeabilized with 0.5% saponin in
water and stained with anti-IFNγ antibody.
For intracellular FoxP3 staining, ConA-stimulated LNC were
harvested after 3 days and stained with anti-CD3, -CD4, -CD25
antibodies. Immunostained cells were subsequently treated with
ﬁxation/permeabilization buffer (eBioscience) and stained with
anti-FoxP3 antibody following the manufacturer’s protocol. Cells
were analyzed on a FACSCalibur™ ﬂow cytometer (BD Bio-
sciences) using CellQuest™ software (BD Biosciences). FACS data
were further analyzed using FlowJo™ software (Treestar, OR,
USA)22.
WESTERN BLOT
Cells were pooled from triplicates and lysed for 30min on ice
with buffer consisting of 25mM Tris·HCl (pH 7.5), 150mM NaCl,
1% (w/v) Triton® X-100, 1mM phenylmethanesulfonyl ﬂuoride
in isopropanol, 1mM Na3VO4 and proteinase inhibitor cocktail
(all from Sigma-Aldrich). Lysates were centrifuged at 10,000× g
for 10min to remove debris, and supernatants were resuspended
in standard sample buffer containing 2% (w/v) sodium dode-
cyl sulfate and 2.5% (v/v) 2-mercaptoethanol. Samples were then
heated at 95˚C for 5min, allowed to cool at ambient tempera-
ture and loaded onto polyacrylamide gels. Electrophoresis was
run at 80–200V. Proteins were transferred onto a polyvinyli-
dene ﬂuoride membrane in a TE 70 semi-dry transfer unit (GE
Healthcare) using a current of 100mA for 65min. Western blot-
ting was performed using anti-rat NOS2 (iNOS) and anti-rat
GAPDH antibodies followed by secondary staining with horse-
radish peroxidase-conjugated IgG. Chemiluminescent substrate
was used to visualize the immunoreactive proteins by horseradish
peroxidase detection.
NO QUANTIFICATION
The nitrite concentration in the medium was measured as an indi-
cator of NO production by virtue of the Griess reaction (Beda
and Nedospasov, 2005). Fifty microliters of cell-free supernatant
from MLR or ConA cultures was mixed with equal volumes of
1% (w/v) sulfanilamide in 5% phosphoric acid and 0.1% (w/v)
naphthylethylenediamine dihydrochloride in water. Absorbance
of the reaction at 540 nm was measured using a Labsystems Multi-
skan® bichromatic plate reader (Titertek Instruments,AL,USA)23
and concentrations were calculated based on a standard curve
of twofold dilutions of sodium nitrate which was assayed in
parallel.
CYTOKINE ASSAYS
For cytokine measurements, supernatants from ConA cultures
were collected after 2–3 days, pooled from triplicate or quadrupli-
cate wells, centrifuged at 1,500× g for 4min to remove cellular
22www.treestar.com
23www.titertek-berthold.com
debris and stored at −80˚C or −20˚C until analysis. Samples
were thawed at 37˚C in a water bath and analyzed using the Bio-
Plex™ Rat Cytokine 9-Plex A Panel (Bio-Rad) according to the
manufacturer’s protocol. Concentrations were determined based
on a standard curve using deﬁned reference samples which were
assayed (Luminex xMAP® Technology; Bio-Rad) in parallel.
STATISTICAL ANALYSIS
Normal distribution of data was assumed and tested by Shapiro–
Wilk’s test. The paired Student’s t test (two-tailed) was used to
evaluate the probability of differences between group means. Sta-
tistical analysis was performedusing SPSS® software version 18.0.1
(SPSS, IL, USA)24.
RESULTS
GENERATION OF MSC LINES FROM RAT BM
We produced MSC lines from the BM of PVG.7B and PVG.1U
MHC-congenic rats. The cells showed adherence to plastic and
spindle-shaped ﬁbroblast-like morphology in culture (data not
shown). They expressed MHC class I, CD44, CD59, CD71, and
CD90 surface markers, but lacked CD11b, CD31, CD45, CD86,
andMHC class II expression (Figure 1). Their potential to develop
into adipocytes and osteocytes was conﬁrmed by in vitro differen-
tiation assays (Zinöcker et al., manuscript submitted). Together,
this data was in accordance with the current deﬁnition of the MSC
phenotype (Dominici et al., 2006; Harting et al., 2008).
RAT BM–MSC INHIBIT ALLO-ANTIGEN AND MITOGEN-INDUCED T CELL
PROLIFERATION IN VITRO INDEPENDENT OF MHC HAPLOTYPE
We tested the ability of MSC to inhibit lymphocyte prolifera-
tion induced by ConA or in allogeneic mixed lymphocyte cul-
tures. ConA stimulation induced proliferation of LNC from
PVG.7B (RT1c) rats as assessed by CFSE dilution and radio-
labeled nucleotide incorporation. Proliferation was fully inhibited
in the presence of PVG.7B MSC at a cell ratio of 1 MSC per 10
LNC (1:10); signiﬁcant suppression was also observed at a ratio
of 1:100 (Figure 2A). The inhibitory effect was not dependent
on the MHC combination of MSC and responder cells as allo-
geneic PVG.1U (RT1u) and syngeneic PVG.7B MSC suppressed
ConA-induced proliferation of PVG.7B responder cells equally
well (Figure 3A). Similarly, both PVG.1U and PVG.7BMSC inhib-
ited antigen-induced proliferation of both PVG.1U and PVG.7B
responder cells in allogeneic MLR with equal efﬁciency (Figure 3B
and data not shown). This suggested that the inhibitory capacity of
MSC did not depend on the MHC-allotype, in line with previous
ﬁndings (Krampera et al., 2003; Le Blanc et al., 2003). Proliferation
of MSC alone was negligible and below the negative control (LNC
proliferation in the absence of a stimulus), which was consistently
less than 10% of the positive control (data not shown). Irradiation
(2000 cGy) of MSC did not reduce their inhibitory capacity sig-
niﬁcantly in ConA- and MLR-induced lymphocyte cultures (data
not shown), suggesting that this property is not dependent on their
ability to proliferate. Cell-free supernatant from MSC culture had
no suppressive effect (data not shown).
24www.spss.com
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FIGURE 1 | Cell surface phenotype of PVG.7B MSC isolated from rat BM.
Ex vivo-expanded MSC express MHC class I (RT1-A), CD44H (H-CAM), CD59
(MAC inhibitor), CD71 (transferrin receptor), and CD90 (Thy-1), but not MHC
class II (RT1-B/D), CD11b (MAC-1), CD31 (PECAM-1), CD45 (LCA), or CD86
(B7-2) as detected by single-color ﬂow cytometry. Representative stainings of
MSC derived from PVG.7B BM are displayed as histograms [x -axis, signal
intensity (log); y -axis, relative cell count (percent of max)] of surface antigens
(solid line) and negative controls (gray histograms).
T CELL PROLIFERATION IN THE PRESENCE OF MSC IS RESTORED BY
ADDITION OF THE iNOS INHIBITOR L-NMMA
We tested inhibitors of different signaling pathways which have
been implicated in immunosuppression by MSC (Meisel et al.,
2004; Aggarwal and Pittenger, 2005; Sato et al., 2007) and found
that the addition of l-NMMA, an inhibitor of iNOS, at the start of
MLR or ConA stimulation (Figure 2 and data not shown) restored
proliferation to normal levels. Conversely, addition of 1-MT, an
IDO inhibitor, or IMC, a COX inhibitor, had no effect. The pres-
ence of all three inhibitors in lymphocyte culture hadno additional
effect compared to l-NMMA alone (Figure 2B). l-NMMA fully
reversed the proliferative arrest of both CD4+ and CD8+ T cells
which were equally affected by MSC inhibition (data not shown).
Together, these data indicated that rMSC use iNOS to suppress T
cell proliferation in vitro.
MSC EXPRESS iNOS AND PRODUCE NO IN RESPONSE TO LYMPHOCYTE
ACTIVATION
Our ﬁndings suggested that the production of NO through iNOS
was responsible for the suppression of T cell proliferation by
rMSC. To test this hypothesis further, we measured the expres-
sion of iNOS by Western blot. iNOS was only detected in ConA
cultures upon addition of MSC (Figure 4A) and correlated with
the number of MSC present. iNOS was not detected in cultures
of MSC alone, which suggested that its expression was induced in
co-cultures with activated T lymphocytes. We also measured the
concentration of nitrate as a proxy of NO (Beda and Nedospasov,
2005) and found that NO levels correlated with the observed iNOS
levels. Neither MSC nor ConA-activated LNC cultures produced
signiﬁcant levels of NO (Figure 4B and data not shown). Notably,
addition of l-NMMA did not affect iNOS protein levels (data not
shown) but completely abrogatedNOproduction (Figure 4B).We
obtained identical results from MLR:MSC co-cultures (unpub-
lished observations). The upregulation of iNOS in MSC co-
cultureswith stimulated lymphocytes correlatedwith the observed
dose-dependent inhibition of proliferation (as shown in Figures 2
and 3) and thus provided further evidence that inducible NO pro-
duction represents a key mechanism for the suppressive capacity
of rMSC.
IMMUNOSTIMULATORY CYTOKINES INDUCE iNOS EXPRESSION IN
MSC
It has been proposed that MSC depend on “licensing” in order
to assume immunosuppressive functions, e.g., by stimulation
through IFNγ or a TLR3 ligand (Krampera et al., 2006; Waterman
et al., 2010; Dazzi and Krampera, 2011). Furthermore, it has been
shown that iNOS expression is induced in response to synergis-
tic stimulation by pro-inﬂammatory cytokines in mMSC (IFNγ
together with either TNF or IL1 signals; Ren et al., 2008; Ren
et al., 2009), and we therefore tested whether this was the case
also for rMSC. Different combinations of IFNγ, TNFα, and TLR
agonists induced iNOS expression in rMSC as judged by West-
ern blot analysis. Incubation with TNFα for 24 h was sufﬁcient to
induce iNOS expression and increase NO concentrations in fresh
MSC cultures (Figure 5A). Conversely, addition of IFNγ did not
activate iNOS at the concentrations tested (titrations of 15 up to
5000UmL−1, data not shown) but potentiated the effect of TNFα
resulting in signiﬁcantly higher levels of both iNOS expression
and NO compared with addition of TNFα alone (Figure 5A). LPS,
a TLR4 agonist, or poly-I:C, a TLR3 agonist, resulted neither in
iNOS expression nor NO production by MSC, in contrast to rat
macrophages used as positive control (Figure 5A; Figure A1 in
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FIGURE 2 | MSC mediate suppression of mitogen-inducedT cell
proliferation through iNOS. (A) LNC from PVG.7B rats were labeled with
CFSE and cultured in the presence of ConA for 3 days. Dilution of CFSE
intensity was measured by ﬂow cytometry to quantify lymphocyte
proliferation. PVG.7B MSC were added at the start of culture at MSC:LNC
ratios of 1:10 (left panel) or 1:100 (right panel), either alone (shaded off-set
histograms) or together with inhibitors of IDO (1-MT, 1mM; dotted line),
COX (IMC, 5μgmL−1; dashed line), or iNOS (L-NMMA, 1mM; solid line).
Proliferation in the absence of MSC is also shown (ConA–LNC, black
histograms). MSC addition resulted in a complete or partial inhibition of
ConA-induced proliferation at 1:10 and 1:100 MSC:LNC ratios, respectively.
The proliferative response was fully restored by addition of L-NMMA while
1-MT or IMC had no effect. (B) In the same experimental set-up as shown
in (A), inhibitors were added to ConA-stimulated LNC cultures in the
absence or presence (MSC:LNC ratio 1:10) of MSC. The percentage of
CFSElo cells was used as a measure of cells that had undergone one or
several cell divisions. The gate shown in (A) marks the distinction between
CFSElo and non-dividing CFSEhi cells. Data are representative of three
independent experiments and are shown as mean and SD of triplicates.
Appendix). LPS synergized with IFNγ in inducing iNOS expres-
sion in MSC, albeit with variable potency, while simultaneous
stimulation with poly-I:C and IFNγ had no effect (Figure 5A;
Figure A1 in Appendix).
Supernatants from stimulated LNC cultures (allogeneic MLR
orConAculture) also led to a potent induction of iNOS (Figure 5B
and data not shown) in MSC. The concentrations of NO in
the culture medium were concordant with the observed protein
expression levels. Induction of iNOS and NO production was
inhibited by addition of anti-IFNγ antibody and, more potently,
anti-TNFα antibody either alone or in combination (Figure 5B).
These data indicate that the inﬂammatory cytokine TNFα has a
key role in priming MSC for their immunosuppressive function,
and that IFNγ potentiates this effect.
FIGURE 3 | Syngeneic and allogeneic MSC blockT cell proliferation in
MLR and ConA-stimulated cultures with similar potency. PVG.7B and
PVG.1U MSC were added at the start of LNC cultures [values on y-axis
signify the common logarithm (log) of MSC:LNC cell ratios, i.e., 1:10 (−1),
1:100 (−2), 1:1000 (−3)] and proliferation was assessed by radio-labeled
thymidine incorporation for the last 20 h of co-incubation in vitro. Inhibition
was calculated relative to the positive control (normal proliferation in the
absence of MSC; black bars) as described in Section “Materials and
Methods.” (A) PVG.7B LNC responder cells were cultured in the presence
of syngeneic (PVG.7B; white bars) or allogeneic (PVG.1U; dotted bars) MSC
and ConA for 3 days. (B) PVG.1U LNC responder cells were cultured in the
presence of irradiated PVG.R23 stimulator cells and syngeneic (PVG.1U;
white bars) or allogeneic (PVG.7B; dotted bars) MSC for 4 days. Proliferation
was efﬁciently suppressed by both syngeneic and allogeneic MSC in a cell
dose-dependent manner. Data from representative experiments are shown
as mean and SD of quadruplicates (A) or triplicates (B).
MSC-MEDIATED INHIBITION OF CYTOKINE SECRETION BY ACTIVATED
T CELLS IS NOT DEPENDENT ON iNOS ACTIVITY BUT ON
COX-MEDIATED PRODUCTION OF PROSTAGLANDIN
Next, we tested the inﬂuence of MSC on the cytokine secretion
patterns of ConA-stimulated lymphocytes. Although iNOS was
important for MSC-mediated inhibition of T cell proliferation,
this factor could not explain the inhibitory effect on IFNγ
production as evaluated by intracellular ﬂow cytometry fol-
lowing addition of l-NMMA to the LNC–MSC co-cultures
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FIGURE 4 | MSC express iNOS and produce NO in response to
lymphocyte stimulation. (A) 1×105 ConA-stimulated PVG LNC were
cultured in the absence (CTR) or presence of syngeneic PVG.7B MSC [log
(MSC:LNC)] and expression of iNOS was analyzed after 24 h. iNOS was
detected in co-cultures of ConA–LNC with MSC and correlated with the
numbers of MSC present. (B) In the same set-up as shown in (A) the
amount of nitrate (shown as the mean and the SD of triplicates) as a proxy
for NO concentration was determined in the absence () or presence ()
of L-NMMA. Addition of L-NMMA abolished NO levels produced in
MSC:LNC co-cultures. NO was not detected in the absence of MSC (CTR).
Data are representative of three independent experiments.
(Figures 6A,B). We further measured cytokine proﬁles by mul-
tiplex analysis and found that MSC constitutively secreted IL6
and vascular endothelial growth factor (VEGF) but not other
cytokines analyzed (data not shown). The addition of MSC
resulted in an accumulation of IL6 and VEGF also in ConA-
stimulated LNC–MSC co-cultures (Figure 6C) as reported pre-
viously (Djouad et al., 2007). Addition of neutralizing concen-
trations (2μgmL−1) of anti-rat IL6 antibody to the co-culture
failed to reverse inhibition (data not shown), in contrast to pre-
vious studies of human and mouse MSC (Di Nicola et al., 2002;
Djouad et al., 2007; Najar et al., 2009). LNC secreted signiﬁcant
amounts of the cytokines IL18, TNFα, and in particular IFNγ
in response to ConA, which were markedly reduced when MSC
were present. The inhibitory effect was proportionate to the num-
bers of MSC added (Figure 6C and data not shown). Addition of
recombinant rat IFNγ (1000UmL−1) to the co-culture failed to
reverse the suppressive effect (data not shown). Expression lev-
els of IL4 and IL10, cytokines which are typically considered as
anti-inﬂammatory, were not increased in co-culture supernatants
(data not shown).
Addition of l-NMMA had no effect on MSC-mediated mod-
ulation of cytokine secretion in co-culture experiments, and the
same was true for the IDO antagonist 1-MT. By contrast, addition
of the COX inhibitor indomethacin resulted in a striking reversal
of inhibition of IFNγ and TNFα secretion at a MSC:LNC ratio
of 1:100, but not at the highest ratio of 1:10 (Figure 6C). This
result suggested that MSC can inhibit T cell mediated secretion of
inﬂammatory cytokines by COX-dependent synthesis of PGE2.
INHIBITION OF PROLIFERATION BUT NOT CYTOKINE PRODUCTION IS
DEPENDENT ON CO-LOCALIZATION OF MSC AND T CELLS
The immunosuppressive effect of hMSC depends on soluble fac-
tors such as IDO, PGE2, hepatocyte growth factor and transform-
ing growth factor β1 (Di Nicola et al., 2002; Meisel et al., 2004;
Aggarwal and Pittenger, 2005) and does not require cell contact
(Hoogduijn et al., 2010) although there have been reports that
co-localization of MSC with lymphocytes augmented inhibition
(Krampera et al., 2003). mMSC require proximity for the effec-
tive inhibition of T cells by short-range activity of NO (Ren et al.,
2008). Therefore, we examined whether inhibition of T cell effec-
tor function by MSC in the rat depended on cell-to-cell contact
or if other soluble factors might be important. Physical separation
of MSC from LNC using transwell membrane inserts restored
ConA-stimulated proliferation which was inhibited in co-cultures
where LNC and MSC were in contact (Figure 7A), indicating that
suppression of proliferation required close proximity of MSC and
target cells. In marked contrast, the cytokine secretion proﬁles
in these cultures were altered irrespective of cell-to-cell contact
(Figure 7B). IL6 and VEGF were increased to similar levels when
MSC and LNC were either co-localized or separated (data not
shown). Inﬂammatory cytokines were signiﬁcantly reduced in the
presence of MSC in either experimental set-up (Figure 7B). These
latter data showed that inhibition of cytokine expression required
a soluble factor, likely PGE2, and provided further evidence that
this property of rMSC is not dependent on close cellular contact.
TREG CELL NUMBERS ARE REDUCED IN STIMULATED LYMPHOCYTE
CO-CULTURES WITH MSC
We also analyzed the effect of MSC on the CD4+CD25hiFoxP3+
Treg cell population using mitogen-induced lymphocyte cultures.
The proportion of Treg cells was signiﬁcantly diminished in the
CD4+ T cell population by addition of MSC at the start of the
culture (Figure 8). This ﬁnding is in contrast to a number of
previous studies which have demonstrated the induction of Treg
cells by MSC in the human system (Aggarwal and Pittenger, 2005;
Di Ianni et al., 2008; English et al., 2009; Ghannam et al., 2010;
Mougiakakos et al., 2011). It should be noted that the functional
potential of these Treg-like cells has not been tested in the present
study.
DISCUSSION
Herein we show that rat BM-derived MSC up-regulate iNOS in
response toTNFα and IFNγ secreted by activated lymphocytes and
produce NO, which exerts a potent inhibitory effect on the pro-
liferative T cell response to mitogen or allogeneic stimuli in vitro.
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FIGURE 5 |Tumor necrosis factor α and IFNγ synergistically induce
iNOS expression and NO production by MSC. 1×104 MSC (PVG.7B)
were stimulated for 24 h with combinations of IFNγ, TNFα, and aTLR
agonist (A) or by medium supernatants from ConA-activated LNC (PVG.7B
or PVG.1U) cultures (B). Pooled triplicates and quadruplicates, respectively,
were analyzed for iNOS expression by Western blot with GAPDH assayed as
a loading control. Nitrate concentrations were determined in the culture
supernatants of the same wells (bottom panels). (A) MSC produced iNOS
(130 kDa) in response to TNFα (25 ngmL−1) alone or together with IFNγ
(100UmL−1) or by a combination of IFNγ and LPS (100 ngmL−1). Nitrate
concentration levels correlated with the observed levels of iNOS protein
expression. The dotted line indicates baseline NO production without
cytokines added. The R2 macrophage cell line was used as positive control
for iNOS expression. (B) Supernatants from ConA-stimulated
(ConA–LNC-sn) and unstimulated LNC cultures as a control (LNC-sn;
baseline) were added to MSC cultures. Neutralizing antibodies (each
10μgmL-1 ﬁnal concentration) against either IFNγ or TNFα or both
(indicated) were added at the start of culture and incubated for 24 h. iNOS
was induced by addition of supernatant from stimulated LNC cultures and
was blocked by IFNγ-speciﬁc antibody and, more potently, by TNFα-speciﬁc
antibody alone or in combination. Nitrate concentrations correlated with the
observed iNOS expression levels. Data are representative of four
independent experiments. Nitrate concentration data are shown as the
mean and the SD of triplicates or quadruplicates.
The present study supports an important but not exclusive role of
iNOS in the immunosuppressive function of MSC in rodents (Oh
et al., 2007; Sato et al., 2007; Ren et al., 2008). COX-dependent
PGE2 is apparently also involved, in the inhibition of IFNγ and
TNFα secretion by activated T cells.
To our knowledge, the only study that has investigated the
immunosuppressive function of rMSC via iNOS to date (Cha-
bannes et al., 2007) showed an effect in combination with heme
oxygenase-1, but not a critical role for iNOS per se. Furthermore,
that study showed that stimulation with recombinant IFNγ alone
resulted in detectable expression of iNOS, which is in contrast to
our ﬁndings showing that TNFα is sufﬁcient and IFNγ is not
required. This difference could be related to variations in cell
isolation protocols, culture conditions, or between different rat
strains. The MSC line generated from LEW.1A BM by Chabannes
et al. (2007) were applied before the fourth passage and a minor-
ity of myeloid cells present in this population (3.2% of the cells
expressedCD45) could account for the reported detection of iNOS
expression in response to IFNγ.
Tumor necrosis factor α, a potent mediator of immune stim-
ulation, induced iNOS expression in rMSC in vitro without a
requirement for auxiliary signals, andneutralizing theTNFα signal
in the supernatant from stimulated lymphocyte cultures abolished
it, underlining the importance of this cytokine in MSC modula-
tion of T cell activation. The pro-inﬂammatory cytokine IFNγ has
also been ascribed an important role in the inhibition of T cell
responses mediated by MSC (Krampera et al., 2006; Ryan et al.,
2007). IFNγ levels were markedly reduced after addition of MSC
to LNC cultures and attempts to restore T cell proliferation by
addition of exogenous IFNγ were unsuccessful. Although IFNγ
did not by itself induce iNOS expression in MSC it did show a
synergistic effect in combination with TNFα or certain TLR lig-
ands (LPS, but not poly-I:C) in support of studies performed in
the mouse (Oh et al., 2007; Ren et al., 2008, 2009). This could
explain why blocking the IFNγ signal by addition of anti-IFNγ
antibody resulted in a signiﬁcant reduction of iNOS expression in
co-culture experiments as others also have shown (Oh et al., 2007;
Ren et al., 2008).
Our data are in agreement with reports that have argued for
“licensing” of MSC to acquire suppressor functionality (Water-
man et al., 2010; Dazzi and Krampera, 2011). Collectively, our
results support a model for the regulation of suppressor functions
by rat BM stromal cells where MSC are primed by inﬂammatory
signals, e.g., immunostimulatory cytokines, primarily TNFα, to
induce iNOS expression leading to the accumulation of NO and
in turn the inhibition of proliferation of activated T cells in the
immediate proximity. In addition, MSC effectively shut off the
generation of inﬂammatory cytokines by activated T cells (Ren
et al., 2008) via a soluble factor dependent on COX activity, likely
PGE2.
The mechanisms employed to achieve immunosuppression are
not identical in different species. In mMSC (Ren et al., 2008), as
in rMSC, iNOS expression seems critically important for the inhi-
bition of T cell proliferation. Our data imply that the cytokine
requirement of MSC to activate this inhibitory pathway is not
identical in rats (TNFα alone is sufﬁcient) and mice (IFNγ and
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FIGURE 6 | MSC inhibition of IFNγ andTNFα secretion is not dependent
on iNOS activity, but on COX-dependent production of prostaglandin.
(A,B) MSC (PVG.7B) were added at the indicated dilutions [log (MSC:LNC)] at
the start of ConA–LNC (PVG.7B) cultures. Cells from triplicate wells were
pooled after 24 h and the number of IFNγ-positive T cells (IFNγ+CD3+
lymphocyte gate, values indicate relative frequencies) determined by ﬂow
cytometry. Inhibition of iNOS by L-NMMA (bottom row and shaded bars) did
not inﬂuence the MSC-mediated suppression of IFNγ expression (top row
and unshaded bars). Controls in (B) show IFNγ production byT cells alone in
the presence (black) or absence (light gray) of ConA. (C) MSC (PVG.1U) were
added at the indicated cell ratios [log] at the start of ConA–LNC (PVG.7B)
cultures in the absence (white bars) or presence of IDO (1-MT, 1mM; circles),
PGE2 (IMC, 5μgmL−1; diamonds), or iNOS (L-NMMA, 1mM; squares)
inhibitors. Cytokine concentrations in the culture supernatants were
determined after 3 days of incubation. As a control (CTR) was used
supernatant from ConA–LNC culture without MSC. Levels of IL6 and VEGF
were signiﬁcantly increased while IFNγ andTNFα were signiﬁcantly reduced
in a MSC dose-dependent manner. Addition of L-NMMA or 1-MT had no effect
on the cytokine expression proﬁles. Addition of IMC reversed in part the
suppression of IFNγ andTNFα by MSC. Data are representative of two
independent experiments and are shown as the average of duplicates; OR,
data point out of detection range.
FIGURE 7 | MSC-mediated inhibition of proliferation, but not
cytokine secretion requires close cellular contact. (A) 5×104 MSC
(PVG.7B) were cultured together with ConA (3μgmL-1)-stimulated
LNC (5×105, i.e., a cell ratio of 1:10) either separate from LNC
(PVG.7B) in transwell membrane inserts (no contact) or co-localized
(cell contact) for 3 days. Relative inhibition of proliferation measured
as 3H-TTP incorporation is shown as the mean and the SD of
triplicates. Cell proliferation was inhibited by MSC only when in
proximity to target cells (P =0.001). (B) In the same set-up as shown
in (A) increasing numbers of MSC [log] were co-cultured with
ConA–LNC in transwell plates either separately (crossed squares) or
co-localized (unﬁlled squares). Cytokine concentrations were assayed
in the culture supernatants after 3 days (shown as the average of
duplicates). IL18, IFNγ, andTNFα were signiﬁcantly reduced in a MSC
dose-dependent, contact-independent manner. OR, data point out of
range.
www.frontiersin.org April 2012 | Volume 3 | Article 62 | 9
Zinöcker and Vaage MSC inhibit proliferation through iNOS
FIGURE 8 | MSC diminish the proportion of CD4+CD25hiFoxP3+ Treg-like
cells in ConA-stimulated lymphocyte cultures. MSC (PVG.7B) were added
at the start of ConA-stimulated LNC cultures in vitro. The frequencies of Treg
cells were analyzed after 3 days by ﬂow cytometry. Representative plots
depict in (A) the gating of lymphocytes (lymphocyte gate not shown) for
CD3+CD4+CD25hiFoxP3+cells in the absence or presence of MSC (MSC:LNC
ratio of 1:10). (B)The relative fraction of Treg cells among CD4+ T cells (means
and SD of triplicates) was reduced compared to control (black bar) in a MSC
dose-dependent manner. Data are representative of three independent
experiments.
any of the cytokines TNFα, IL1α, or IL1β are required). Ren et al.
(2009) demonstrated that other inhibitory mechanisms, namely
the secretion of IDO, but not iNOS, were employed by monkey
and human BM-derived MSC in this context.
MSC-mediated inhibition of secretion of IFNγ and TNFα by
activated T cells was dissociated from iNOS activity and NO, as
demonstrated by transwell cultures and biochemical inhibition of
iNOS. Our data are in contrast with a study of mMSC, which
suggested that iNOS is involved in inhibiting IFNγ production by
T cells stimulated with anti-CD3/CD28 beads in the presence of
IL12 and anti-IL4 antibody (Oh et al., 2007). Our study identiﬁes
PGE2 as a candidate soluble factor responsible for the dampening
of inﬂammatory cytokine production by activated lymphocytes,
in agreement with a previous study of hMSC (Aggarwal and Pit-
tenger, 2005). Taken together, it can be concluded that rMSC
utilize different pathways to regulate proliferation and cytokine
production by T cells. The species-speciﬁc mechanisms regulating
the suppression of immune cell activation and effector functions
through BM stromal progenitor cells should be investigated fur-
ther, because this research might have important implications for
the use of MSC or related cell types in the clinical treatment of
GVHD, autoimmune diseases or other syndromes of undesired T
cell activity.
In a separate series of experiments, we have tested the ther-
apeutic potential of the MSC lines presented here in a model of
experimentalGVHD induced by donor lymphocyte infusions after
MHC-mismatched allogeneic stem cell transplantation (Zinöcker
et al., 2011a). Despite their marked inhibitory potential in vitro,
repeated systemic injections of MSC did not improve GVHD
in these experiments even after prestimulaton with IFNγ and
TNFα to boost the iNOS pathway in MSC (Zinöcker et al., man-
uscript submitted). This suggests that their immunosuppressive
efﬁcacy is limited with respect to GVHD-related morbidity and
mortality.
We show here that rMSC suppress proliferation in vitro only
when in close proximity to stimulated T cells through short-range
activity of NO. The route of administration may determine the
effectiveness of treatment if co-localization of MSC is required
for the efﬁcient suppression of alloreactive immune cells in vivo.
We have previously observed by in vivo imaging that MSC which
expressed enhanced green ﬂuorescence protein transgenically
accumulated in the lungs shortly (within minutes) after intra-
venous injection but did not detect these cells at that site or in
other organs after several days in vivo and post mortem (unpub-
lished observations). Failure to migrate to sites of allopriming and
alloreactivity in GVHD is a plausible explanation for the observed
lack of efﬁciency of MSC therapy.
Besides NO synthases, arginase 1 is an important enzyme that
regulates l-arginine metabolism and production of NO and has
the ability to inhibit T cell proliferation (Grohmann and Bronte,
2010). We did not address a potential role of arginase 1 in the
suppression of activated T cells by rMSC in this study. If these
cells make use of other, potentially redundant molecular path-
ways to inhibit T cells or other immune cell types, the strength of
NO-dependent immunosuppression observed in this study would
suggest that such alternative mechanisms are of minor importance
regarding MSC-mediated inhibition of T cell proliferation in the
rat species.
MSC have been shown to induce different subtypes of Treg cells
(Aggarwal and Pittenger, 2005; Di Ianni et al., 2008; English et al.,
2009; Ghannam et al., 2010; Mougiakakos et al., 2011) as potential
immunomodulatory mechanisms operating in vivo (Hoogduijn
et al., 2010). Our ﬁnding that CD4+CD25hiFOXP3+ Treg cells
were reduced after ConA-stimulation of T cells in the presence of
rMSCwas inmarked contrast to the studies with hMSC andmakes
it less likely that Treg cells are involved in the observed inhibition of
proliferation or cytokine secretion of activated rat T cells in vitro.
Further experiments could clarify the functional characteristics of
this putative Treg cell type.
Recently, Turley and co-workers presented ﬁndings which
showed that iNOS represents a central pathway employed by both
ﬁbroblastic reticular and lymphoid endothelial cells to regulate
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T cell activation in the lymph nodes of mice (Lukacs-Kornek
et al., 2011). The observed inhibitory effects depended on IFNγ,
TNF and direct cell contact (Lukacs-Kornek et al., 2011) and
correlate well with our observations for rMSC, which displayed
very similar cytokine requirements and inhibitory effects. We
therefore speculate that the enzymatic conversion of NO is a
common feature of stromal cells in rodents (Jones et al., 2007),
which, in combination with PGE2, control T cell expansion at
sites of priming of the adaptive immune system (Lukacs-Kornek
et al., 2011) and subsequent inﬂammation (Nombela-Arrieta et al.,
2011).
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APPENDIX
FIGUREA1 | Comparison of cytokine andTLR ligand requirements for
NO production by macrophages and MSC. R2 macrophages (top panel)
and MSC (PVG.7B; bottom panel) were stimulated for 24 h with IFNγ
(100UmL−1), TNFα (25 ngmL−1), LPS (1μgmL−1), and poly-I:C (1μgmL−1),
either alone or in combination with IFNγ as indicated. R2 macrophages
produced signiﬁcant levels of NO in response to theTLR agonists LPS and
poly-I:C as well as IFNγ. In MSC, NO was only generated in response to
TNFα but not to the other stimulatory agents. Addition of IFNγ had a
synergistic effect in combination with TNFα or LPS in both macrophages
and MSC. The dotted lines indicate baseline NO production of the
respective cell type without cytokines added.
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